Active substances
Potassium phosphate dibasic + Potassium phosphate monobasic
- US FDA 10
- Health Canada 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML); 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 26 Nov 2019 |
| POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML); 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 26 Nov 2019 |
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML); 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | solution · intravenous | AM REGENT | Prescription | 2 Oct 2023 |
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML); 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | solution · intravenous | AMNEAL | Prescription | 10 Oct 2023 |
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML) | solution · intravenous | SOMERSET THERAPS LLC | Prescription | 11 Jul 2024 |
| POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | solution · intravenous | AMNEAL | Prescription | 26 Jul 2024 |
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML); 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | solution · intravenous | CIPLA | Prescription | 24 Jan 2025 |
| POTASSIUM PHOSPHATES | 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML) | solution · intravenous | HOSPIRA | Prescription | 11 Sep 2025 |
| POTASSIUM PHOSPHATES | 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML); 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML); 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) | solution · intravenous | CAPLIN | Prescription | 12 Mar 2026 |
| POTASSIUM PHOSPHATES | 4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) | solution · intravenous | CMP DEV LLC | Discontinued | 19 Sep 2019 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| POTASSIUM PHOSPHATES | 00804789 | 236 MG / ML; 224 MG / ML | LIQUID · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| POTASSIUM PHOSPHATES INJECTION, USP | 02139545 | 236 MG / ML; 224 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.